Abstract Details

Title Treatment and Disability Trends in a Predominantly Hispanic Pediatric Multiple Sclerosis Cohort from Children Hospital of Los Angeles

Topic MS and Related Diseases

Presentation(s) P02 - (-)

Poster/Presentation
Number 118

Objective

Background BACKGROUND: Initiation of treatment and maintenance is thought to be challenging in pediatric multiple sclerosis.

Design/Methods DESIGN/METHODS: Cross-sectional study of 74 cases with pediatric onset demyelinating disease. Information on demographic, self-reported ethnicity, clinical course, disability, treatment at diagnosis and at follow-up (interval of 3 month, 1 and 2 years) was collected via medical record and phone interview. Cases which had missing information from diagnosis to follow up were excluded (n=21).

Results RESULTS: A total of 53 cases were included. Gender was evenly distributed (F:M 1:1) predominantly of Hispanic background (88%). The average age of diagnosis was 15.4 ±2.7 (Mean±SD), with a lag time from age off symptoms of [sim]1 year. Mean disability scores were 3.6 ±1.8 at diagnosis, 1.2±1.6 at 3 month follow up, 1.1±1.6 at 1 year follow up and 1.6±1.5 at 2 year follow up. A statistically significant difference was noted in disability scores between onset of disease and 2 year follow up (p=0.000012). Over 80% were on a disease modifying treatment. Over 1/3 of cases required a change in therapy at least once while 13% change therapy ?2 times. The most common disease modifying treatment (DMT) initiated was glatiramer acetate (n=25).

Conclusions CONCLUSIONS: In this cohort of patients, predominantly of Hispanic background, with pediatric MS disability scores were lower at follow up than at diagnosis. Despite the low disability scores over time, 37% of patients changed disease modifying therapy (DMT). There is a need for better understanding of effectiveness of DMT in pediatric patients and factors effecting change in treatment. The considerations influencing treatment decisions are likely different in children than adults.

Authors/Disclosures
Megan M. Langille, MD (Harbor UCLA) PRESENTER	Dr. Langille has nothing to disclose.
Lilyana M. Amezcua, MD, FAAN (USC)	Dr. Amezcua has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD serono. Dr. Amezcua has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Amezcua has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Amezcua has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for genentech. The institution of Dr. Amezcua has received research support from National MS Society. The institution of Dr. Amezcua has received research support from Genentech. The institution of Dr. Amezcua has received research support from Bristol Myers Squibb Foundation. The institution of Dr. Amezcua has received research support from NIH NINDS. The institution of Dr. Amezcua has received research support from Sanofi/Genzyme. The institution of Dr. Amezcua has received research support from Alexion.
Quyen N. Luc, MD	No disclosure on file
Gavin Giovannoni, MD (QMUL)	Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck KGaA. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche-Genentech. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Moderna. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Astoria Biologica. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Zenas. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Medscape.

��ɫ��

��ɫ��